On September 18, 2024, Satellos Bioscience Inc. announced that the first participant has been dosed in a Phase 1 clinical study of SAT-3247. SAT-3247 is a novel, oral small molecule drug targeting AAK1 that is designed to regenerate skeletal muscle in Duchenne muscular dystrophy and other degenerative or injury conditions involving muscle tissue. Read the full press release below.
Press release highlights:
- The first healthy volunteer has been dosed in the first component of the Phase 1 study
- Initial safety and pharmacokinetic data expected in Q4 2024
- Initiation of the second component of the Phase 1 study, in adult DMD patients, expected in Q1 2025
What is SAT-3247?
SAT-3247 is an oral, small molecule drug candidate designed to target the root cause of muscle loss in degenerative diseases, initially in Duchenne. SAT-3247 presents a novel mechanism of action to restore impaired muscle regeneration caused by the absence of functional dystrophin.
Defeat Duchenne Canada is pleased to be currently funding the work of Dr. Mike Rudnicki, who is the Director of the Regenerative Medicine Program at the Ottawa Research Institute and is also the Chief Scientific Officer of Satellos Bioscience Inc.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: